Great article. I've always preferred device companies to drug companies in the healthcare/biotech sectors. It's often a slower climb given that it takes time for devices to get market penetration, but there isn't the risk of failed trials or non-approvals.
I think CMP has the potential to grow significantly over the next few years. The question is can management unlock this potential? They are showing the right signs with the re-capitalization reviews and re-focus on core business and emerging opportunities, but there is a long way to go.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $53.82M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 28.0¢ | $410 | 1.464K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 20999 | 1 |
View Market Depth
| Last trade - 10.17am 18/07/2025 (20 minute delay) ? |
| CMP (ASX) Chart |